Abstract
Inflammatory breast cancer (IBC) is the most aggressive and lethal breast cancer subtype, but lags in biomarker identification. Here, we used an improved Thermostable Group II Intron Reverse Transcriptase RNA sequencing (TGIRT-seq) method to simultaneously profile coding and non-coding RNAs from tumors, PBMCs, and plasma of IBC and non-IBC patients and healthy donors. Besides RNAs from known IBC-relevant genes, we identified hundreds of other overexpressed coding and non-coding RNAs (p≤0.001) in IBC tumors and PBMCs, including higher proportions with elevated intron-exon depth ratios (IDRs), likely reflecting enhanced transcription resulting in accumulation of intronic RNAs. As a consequence, differentially represented protein-coding gene RNAs in IBC plasma were largely intron RNA fragments, whereas those in healthy donor and non-IBC plasma were largely fragmented mRNAs. Potential IBC biomarkers in plasma included T-cell receptor pre-mRNA fragments traced to IBC tumors and PBMCs; intron RNA fragments correlated with high IDR genes; and LINE-1 and other retroelement RNAs that we found globally up-regulated in IBC and preferentially enriched in plasma. Our findings provide new insights into IBC and demonstrate advantages of broadly analyzing transcriptomes for biomarker identification. The RNA-seq and data analysis methods developed for this study may be broadly applicable to other diseases.
Competing Interest Statement
AML is an inventor on patents owned by the University of Texas at Austin for TGIRT enzymes and other stabilized reverse transcriptase fusion proteins and methods for non-retroviral reverse transcriptase template switching. AML, JY, and HX are inventors on a patent application filed by the University of Texas for the use of intron RNAs as biomarkers. DW, XW, JY, HX, EAF-K, NTU, and AML are inventors on a patent application filed jointly by UT Austin and MD Anderson entitled "Methods and Compositions for Diagnosing, Treating and/or Preventing Inflammatory Breast Cancer" based on potential RNA biomarkers identified in this study.
Funding Statement
National Institutes of Health grant R35 GM136216 (AML), Welch Foundation grant F-1607 (AML), Breast Cancer Research Foundation grant BCRF-20-164 (NTU), National Institutes of Health grant 1R01CA258523-01A1 (NTU), the Morgan Welch Inflammatory Breast Cancer Research Program (NTU), and the State of Texas Rare and Aggressive Breast Cancer Research Program Grant (NTU).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ten IBC patient FFPE tumor tissue and paired PBMC and plasma samples, 4 non-IBC patient FFPE tumor tissue and paired PBMC and plasma samples, 2 additional non-IBC patient PBMC and plasma samples, and 13 healthy donor PBMC and plasma samples were obtained from the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic at MD Anderson Cancer Center (MDACC). Each patient and healthy donor gave written informed consent. This study was approved by the MDACC Institutional Review Board. IBC was diagnosed by strictly following the criteria of the American Joint Committee on Cancer (73). All IBC patient tissues were reviewed by a pathologist (Savitri K.) to ensure accurate diagnosis and tumor cellularity >60%.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Co-first authors
Data Availability
The TGIRT-seq datasets in this manuscript are listed in the Supplemental File and have been deposited in the National Center for Biotechnology Information Sequence Read Archive (accession number: PRJNA954747).
